NeuroSense announced final results from a biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease. Preliminary results from the study showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results. TDP-43 has been found in up to 57% of AD cases. NeuroSense’s platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis, and is now being evaluated in a Phase 2b ALS double-blind clinical trial. NeuroSense believes these most recent biomarker results show the importance of TDP-43 pathology in AD and suggest the potential efficacy of NeuroSense’s platform technology in Alzheimer’s disease. NeuroSense plans to commence a Phase 2 double-blind proof-of-concept study in Alzheimer’s disease in the first half of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NRSN:
